{"entity":{"id":"paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016","kind":"paper","name":"BMT CTN 0803/AMC 071: autologous haematopoietic cell transplantation for HIV-related lymphoma","aka":[],"tldr":"People with HIV whose lymphoma had relapsed did as well after high-dose chemotherapy and a stem cell transplant as matched HIV-negative patients, with 87 percent alive at one year.","summary":"Single-arm phase 2 trial of the Blood and Marrow Transplant Clinical Trials Network and AIDS Malignancy Consortium: 43 HIV-infected patients with chemotherapy-sensitive relapsed or persistent aggressive B-cell or Hodgkin lymphoma were enrolled and 40 underwent autologous transplant after BEAM conditioning with consistent peri-transplant antiretroviral management.\n\nAt a median follow-up of 24.8 months one- and two-year overall survival were 87.3 and 82 percent, two-year progression-free survival 79.8 percent and one-year transplant-related mortality 5.2 percent; neutrophil and platelet recovery took 11 and 18 days; outcomes did not differ from 151 matched registry controls.","asOf":"2026-09-22","links":[{"label":"Blood 2016","url":"https://doi.org/10.1182/blood-2015-08-664706"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/27297790/"}],"tags":[],"related":[],"cancers":["hiv-associated-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["bmt-ctn-0803"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"journal":"Blood","year":2016,"doi":"10.1182/blood-2015-08-664706","pmid":"27297790","authors":"Alvarnas JC, Le Rademacher J, Wang Y, et al.","paperType":"observational","findings":["One-year overall survival 87.3 percent (95% CI 72.1 to 94.5) and two-year 82 percent (65.9 to 91).","Two-year progression-free survival 79.8 percent; one-year transplant-related mortality 5.2 percent.","No significant difference from 151 matched HIV-negative controls."],"whatItMeans":"HIV infection is not a reason to withhold autologous transplant from patients with relapsed lymphoma who meet standard transplant criteria.","caveats":["Small single-arm study in patients with controlled HIV and chemotherapy-sensitive disease."],"changedPractice":true,"participants":43},"route":"/key-papers/paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016/","neighbours":{"cancer":[{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/"}],"trial":[{"id":"bmt-ctn-0803","kind":"trial","name":"BMT CTN 0803","route":"/trials/bmt-ctn-0803/"}],"journal":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/"}]}}